All In MedTech

FDA Clearance Tracker · P150031-S040

Vercise PC, Vercise Gevia and Vercise Genus DBS Systems

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 20, 2021 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 20, 2021

Approved

Time to decision

232 days

Received Mar 2, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P150031-S040
Device name
Vercise PC, Vercise Gevia and Vercise Genus DBS Systems
Applicant location
Valencia, CA
Received
Mar 2, 2021
Decided
Oct 20, 2021
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P150031

Device type

Device class
Class III

Every decision under product code PJS

FDA's approval statement

As written in FDA's record.

Approval to expand the current IFU to include: "Unilateral thalamic stimulation of the ventral intermediate nucleus (VIM). The device is indicated for the suppression of tremor in the upper extremity. The system is intended for use in patients who are diagnosed with essential tremor or parkinsonian tremor not adequately controlled by medications and where the tremor constitutes a significant functional disability."

Source documents

Other decisions for Boston Scientific Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.